Abstract:Introduction: Cetuximab (CTX) is an effective targeted drug for the treatment of metastatic colorectal cancer, but it is effective only in patients with wild-type KRAS genes. Even in this subset of patients, the sensitivity of CTX in patients with right hemi-colon cancer is much lower than that in patients with left hemi-colon cancer. This significantly limits its clinical application. Therefore, further elucidation of the underlying molecular mechanisms is needed. N-myc downstream-regulated gene 1 (NDRG1) plays an important role in solid tumor invasion and metastasis, but whether it can influence CTX sensitivity has not been thoroughly investigated. Objective: Our study aimed to identify a novel mechanism by which NDRG1 affects CTX sensitivity. Methods: Through mass spectrometry analysis of our previously constructed CTX-resistant RKO and HCT116 cells, we found that the signal transducer and activator of transcription-1 (Stat1) might be a potential target of NDRG1. By knocking out NDRG1 or/and Stat1 genes, we then applied the loss-of-function experiments to explore the regulatory relationship between NDRG1 and Stat1 and their roles in the cell cycle, epithelial-mesenchymal transition (EMT), and the sensitivity to CTX in these two colorectal cancer (CRC) cells. Finally, we used the nude-mouse transplanted tumor model and human CRC samples to verify the expression of NDRG1 and Stat1 and their impact on CTX sensitivity in vivo. Results: Stat1 was upregulated in CTX-resistant cells, whereas NDRG1 was downregulated. Mechanically, NDRG1 was inversely correlated with Stat1 expression. It suppressed CRC cell proliferation, migration, and invasion, and promoted apoptosis and epithelial-mesenchymal transition (EMT) by inhibiting Stat1. In addition, NDRG1 directly interacted with Stat1 and promoted Smurf1-induced Stat1 ubiquitination. Importantly, this novel NDRG1-dependent regulatory loop also enhanced CTX sensitivity both in vitro and in vivo. Conclusion: Our study revealed that NDRG1 enhanced the sensitivity to Cetuximab by inhibiting Stat1 expression and promoting its ubiquitination in colorectal cancer, elucidating NDRG1 might be a potential therapeutic target for refractory CTX-resistant CRC tumors. But its clinical value still needs to be validated in a larger sample size as well as a different genetic background.

NDRG2 acts as a negative regulator of the progression of small-cell lung cancer through the modulation of the PTEN-AKT-mTOR signalling cascade

N-myc Downstream Regulated Gene 1 Inhibition of Tumor Progression in Caco2 Cells.

N-Myc Downstream-Regulated Gene 2 (NDRG2) As a Novel Tumor Suppressor in Multiple Human Cancers

Knockdown of NDRG1 Promote Epithelial-Mesenchymal Transition of Colorectal Cancer Via NF-κB Signaling.

NDRG2 suppresses the proliferation of clear cell renal cell carcinoma cell A-498

NDRG2 Acts As a Negative Regulator Downstream of Androgen Receptor and Inhibits the Growth of Androgen-Dependent and Castration-Resistant Prostate Cancer

NDRG2 Inhibits Human Cholangiocarcinoma Progression and Is Regulated by LIF/MicroRNA-181c Negative feedback Pathway.

Suppression of MMP-9 activity by NDRG2 expression inhibits clear cell renal cell carcinoma invasion

Expression of NDRG2 in human lung cancer and its correlation with prognosis

NDRG1 enhances the sensitivity to Cetuximab by promoting Stat1 ubiquitylation in colorectal cancer

Abstract 1539: NDRG1 promotes epithelial-mesenchymal transition in lung cancer cells by upregulation of SLUG expression

Microarray profiling of HepG2 cells ectopically expressing NDRG2.

Low NDRG2 Expression Predicts Poor Prognosis in Solid Tumors

The proto-oncogene c-Src and its downstream signaling pathways are inhibited by the metastasis suppressor, NDRG1.

N-myc Downstream-Regulated Gene 2 Expression is Associated with Glucose Transport and Correlated with Prognosis in Breast Carcinoma

Overexpression of N-Myc Downstream-Regulated Gene 2 (NDRG2) Regulates the Proliferation and Invasion of Bladder Cancer Cells in Vitro and in Vivo

Metastasis suppressor, NDRG1, mediates its activity through signaling pathways and molecular motors.

N-myc Downstream-Regulated Gene 1 Inhibits the Proliferation of Colorectal Cancer Through Emulative Antagonizing NEDD4-mediated Ubiquitylation of P21

N‐myc Downstream‐regulated Gene 2 Inhibits Human Cholangiocarcinoma Progression and is Regulated by Leukemia Inhibitory Factor/microrna‐181c Negative Feedback Pathway

Suppression of Invasion and Metastasis of Prostate Cancer Cells by Overexpression of NDRG2 Gene.

A novel molecular marker for early detection and evaluating prognosis of gastric cancer: N-myc downstream regulated gene-1 (NDRG1).